OBJECTIVE: Studies indicate cross-desensitization between opioid receptors (eg, kappa opioid receptor, OPRK1) and chemokine receptors (eg, CXCR4) involved in HIV infection. Whether gene variants of OPRK1 and its ligand, prodynorphin (PDYN), influence the outcome of HIV therapy was tested. METHODS: Three study points, admission to the Women's Interagency HIV Study, initiation of highly active antiretroviral therapy (HAART), and the most recent visit, were chosen for analysis as crucial events in the clinical history of the HIV patients. Regression analyses of 17 variants of OPRK1 and 11 variants of PDYN with change of viral load (VL) and CD4 count between admission and initiation of HAART and initiation of HAART to the most recent visit to Women's Interagency HIV Study were performed in 598 HIV+ subjects, including African Americans, Hispanics, and Whites. Association with HIV status was done in 1009 subjects. RESULTS: Before HAART, greater VL decline (improvement) in carriers of PDYN IVS3+189C>T and greater increase of CD4 count (improvement) in carriers of OPRK -72C>T were found in African Americans. Also, greater increase of CD4 count in carriers of OPRK1 IVS2+7886A>G and greater decline of CD4 count (deterioration) in carriers of OPRK1 -1205G>A were found in Whites. After HAART, greater decline of VL in carriers of OPRK1 IVS2+2225G>A and greater increase of VL in carriers of OPRK1 IVS2+10658G>T and IVS2+10963A>G were found in Whites. Also, a lesser increase of CD4 count was found in Hispanic carriers of OPRK1 IVS2+2225G>A. CONCLUSIONS: OPRK1 and PDYN polymorphisms may alter severity of HIV infection and response to treatment.
OBJECTIVE: Studies indicate cross-desensitization between opioid receptors (eg, kappa opioid receptor, OPRK1) and chemokine receptors (eg, CXCR4) involved in HIV infection. Whether gene variants of OPRK1 and its ligand, prodynorphin (PDYN), influence the outcome of HIV therapy was tested. METHODS: Three study points, admission to the Women's Interagency HIV Study, initiation of highly active antiretroviral therapy (HAART), and the most recent visit, were chosen for analysis as crucial events in the clinical history of the HIVpatients. Regression analyses of 17 variants of OPRK1 and 11 variants of PDYN with change of viral load (VL) and CD4 count between admission and initiation of HAART and initiation of HAART to the most recent visit to Women's Interagency HIV Study were performed in 598 HIV+ subjects, including African Americans, Hispanics, and Whites. Association with HIV status was done in 1009 subjects. RESULTS: Before HAART, greater VL decline (improvement) in carriers of PDYN IVS3+189C>T and greater increase of CD4 count (improvement) in carriers of OPRK -72C>T were found in African Americans. Also, greater increase of CD4 count in carriers of OPRK1 IVS2+7886A>G and greater decline of CD4 count (deterioration) in carriers of OPRK1 -1205G>A were found in Whites. After HAART, greater decline of VL in carriers of OPRK1 IVS2+2225G>A and greater increase of VL in carriers of OPRK1 IVS2+10658G>T and IVS2+10963A>G were found in Whites. Also, a lesser increase of CD4 count was found in Hispanic carriers of OPRK1 IVS2+2225G>A. CONCLUSIONS:OPRK1 and PDYN polymorphisms may alter severity of HIV infection and response to treatment.
Authors: P K Peterson; G Gekker; J R Lokensgard; J M Bidlack; A C Chang; X Fang; P S Portoghese Journal: Biochem Pharmacol Date: 2001-05-01 Impact factor: 5.858
Authors: Imre Szabo; Xiao-Hong Chen; Li Xin; Martin W Adler; O M Z Howard; Joost J Oppenheim; Thomas J Rogers Journal: Proc Natl Acad Sci U S A Date: 2002-07-18 Impact factor: 11.205
Authors: Genya Gekker; Shuxian Hu; Mark P Wentland; Jean M Bidlack; James R Lokensgard; Phillip K Peterson Journal: J Pharmacol Exp Ther Date: 2004-02-02 Impact factor: 4.030
Authors: S Mummidi; S S Ahuja; E Gonzalez; S A Anderson; E N Santiago; K T Stephan; F E Craig; P O'Connell; V Tryon; R A Clark; M J Dolan; S K Ahuja Journal: Nat Med Date: 1998-07 Impact factor: 53.440
Authors: Sylvia Fitting; Shiping Zou; Nazira El-Hage; Masami Suzuki; Jason J Paris; Christina J Schier; José W Rodríguez; Myosotys Rodriguez; Pamela E Knapp; Kurt F Hauser Journal: Curr HIV Res Date: 2014 Impact factor: 1.581